EUCTR2007-004865-17-BG进行中（未招募）不适用
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Benign Prostatic Hyperplasia, based on medical history;
- •2. Voiding symptoms: IPSS = 13;
- •3. 50 years or older (at time of screening);
- •4. Uroflow (max) 5 -15 mL/sec
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Safety concerns
- •1. Urgent need for prostate surgery;
- •2. Serum PSA = 10 ng/ml; a patient with serum PSA > 4 ng/ml (but < 10 ng/ml) is only eligible if prostate cancer has been excluded to the satisfaction of the investigator (e.g. by prostate biopsy).;
- •3. History of allergic reactivity to peptide;
- •4. Clinical significant increase of bleeding time
- •5. Major organ dysfunction, e.g., insulin-dependent diabetes, recent myocardial infarction (within 6 months of enrolment), history of unstable angina or newly diagnosed angina pectoris, current congestive heart failure, uncontrolled hypertension, current serious arrhythmia, use of concomitant Class 1A or Class III antiarrhythmic medications, personal or family history of long QT syndrome, clinically relevant ECG abnormalities (including QT/QTc interval > 450 ms), cancer (considered as not cured) except basal cell or squamous cell carcinoma of the skin or clinically relevant chronic or acute infections;
- •Lack of suitability for the trial:
- •6. Prior surgical treatment of the prostate or bladder;
- •7. Current or recent treatment with sexual hormone drugs or 5a reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior to trial medication at Week 0 or with a blockers or saw palmetto within the last 6 weeks prior to trial medication at Week 0;
- •8. Newly started treatment with tricyclic antidepressants, cholestyramine, disopyramide, ketoconazole, and anticholinergics drugs.;
- •9. Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy;
- •10. History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months;
- •11. Residual urine volume of > 350 mL;
- •12.Neurological, psychiatric disease, drug or alcohol abuse which could interfere with the patient’s proper compliance
研究者
相似试验
进行中（未招募）
1 期
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyEUCTR2007-002598-30-FRAeterna Zentaris GmbH400
进行中（未招募）
1 期
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyBenign Prostatic Hyperplasia (PBH)MedDRA version: 9.1 Level: LLT Classification code 10004446 Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-GBAeterna Zentaris GmbH400
进行中（未招募）
不适用
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study - NDBenign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-ITAETERNA ZENTARIS GMBH400
进行中（未招募）
不适用
Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyBenign Prostatic Hyperplasia (PBH)MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-NLAeterna Zentaris GmbH400
进行中（未招募）
不适用
Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyBenign Prostatic Hyperplasia (PBH)MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-CZAeterna Zentaris GmbH400